Pfizer is trading at a forward P/E of 9 and offers a 6.58% dividend yield, with a 24/7 Wall St. price target of $32.92, implying a 25.76% upside from its current $26.18 price. The company’s non-COVID products are growing steadily, offsetting declines in COVID-related sales. Pfizer plans about 20 pivotal trial starts in 2026, including obesity and oncology assets, supported by cost-saving measures targeting $7.2 billion by 2027. Insider buying and analyst buy ratings reinforce a bullish outlook, though risks include patent expirations, pricing pressures, and a recent non-cash impairment charge. The stock could reach $36.53 in a bull scenario or $28.82 in a bear case, with long-term targets up to $51.27 by 2030 if growth and pipeline execution continue as planned.
In the first half of 2026, smart beta strategies showed mixed results, with momentum and low-volatility funds lagging, while dividend growth funds struggled due to rising yields. However, funds emphasizing companies with strong free cash flow and hig...
Pfizer is navigating a transitional phase aiming for growth by 2029, maintaining its dividend payout to support financial stability despite patent losses and reduced COVID revenues. The company’s dividend payout ratio aligns with management’s long-te...
